Physician profile
James Sullivan
NPI 1467560292
$4,033.88
in general payments reported to CMS, 2019-2025
36 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $200 · 2021: $643 · 2022: $589 · 2023: $187 · 2024: $735 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $486.92 | 2019-2025 | Veltassa, Zemaira |
| Amgen INC. | $482.11 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $446.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $408.04 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $365.32 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $305.11 | 2021-2024 | Benlysta, Nucala |
| Boston Scientific Corporation | $164.89 | 2019 | |
| Akebia Therapeutics INC | $119.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.43 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Bard Peripheral Vascular, INC. | $94.86 | 2019 | |
| Apellis Pharmaceuticals, INC. | $87.46 | 2025 | |
| Fresenius USA Marketing, INC. | $86.59 | 2019-2023 | |
| Renalytix Ai, INC. | $82.60 | 2022 | |
| Genzyme Corporation | $78.49 | 2019-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.85 | 2025 | Dupixent |
| Travere Therapeutics, INC. | $49.54 | 2021-2025 | |
| Tactile Systems Technology INC | $46.63 | 2021-2025 | Nimbl, Flexitouch Plus |
| Calliditas Therapeutics US INC. | $40.83 | 2022-2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $40.11 | 2019-2023 | |
| Pfizer INC. | $38.33 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $37.83 | 2021 | |
| Outset Medical INC | $35.79 | 2025 | |
| Novo Nordisk INC | $33.12 | 2024-2025 | Wegovy, Ozempic |
| Chiesi USA, INC. | $32.37 | 2023-2024 | Elfabrio |
| Aurinia Pharma U.S., INC. | $31.65 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $24.99 | 2021 | |
| Abbott Laboratories | $24.13 | 2021 | |
| Horizon Therapeutics Plc | $22.92 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $21.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.41 | 2024 | |
| United Therapeutics Corporation | $15.47 | 2025 | Tyvaso |
| Scpharmaceuticals INC. | $15.18 | 2024 | |
| Amicus Therapeutics, INC. | $14.54 | 2019 | |
| Baxter Healthcare | $14.23 | 2024 | Hillrom - Vest System Model 105 Home Care |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.